Shineco (SISI) Ignites Growth: $8.7M Tech Deal & Major Singapore Alliance Unleash Dual Engines
BEIJING, Sept. 12, 2025 /PRNewswire/ -- Shineco Inc. (NASDAQ:SISI) ("Shineco" or the "Company"), a developer and commercializer of induced pluripotent stem cell (iPSC) technology platforms, today announced two major strategic advances. Its subsidiary, Xi'an Dong'ao Health Management Co., Ltd. ("Dong'ao Health"), has signed a technology services contract valued at US$8.7 million with Xinke Future Biotechnology (Bazhou) Co., Ltd. for the research and development of "microalgae-derived extracellular vesicles" technology. Separately, a delegation from Singapore's leading biotechnology company, BICC, completed a productive site visit to Dong'ao Health on September 10. The parties reached a broad consensus on key collaboration areas, including establishing a joint laboratory and a technology exchange mechanism, marking a substantive step forward in Shineco's "technology industrialization and global synergy" strategy in the biocellular field.
As the core entity executing Shineco's strategy in the biocellular market, Dong'ao Health's new contract focuses on cutting-edge microalgae-derived extracellular vesicles technology. The service period runs from August 25, 2025, to December 31, 2026, with the goal of building a comprehensive, end-to-end R&D system from basic research to process development and product translation. Specific tasks include functional validation during the basic research phase; breaking bottlenecks in large-scale (e.g., hectoliter-scale) separation and extraction processes to achieve mass production; and developing at least two therapeutic products with full regulatory support to effectively transition the technology from the lab to the market.
This contract provides clear near-term financial momentum for Shineco. The total value of US$8.7 million will be paid in phases, with an initial payment of US$560,000 already received. Subsequent payments are tied to R&D milestones, ensuring stable revenue recognition and creating long-term profit growth drivers through the "develop once, deploy multiple times" nature of the technology.
"This contract is a powerful validation of our strategy to monetize cutting-edge research and create near-term revenue," said Jennifer Zhan, CEO of Shineco. "Coupled with our strategic alliance with BICC, it provides two clear, synergistic engines for growth that strengthen our domestic business while accelerating our international expansion."
Concurrent with this R&D progress, Shineco's international cooperation achieved a key milestone. BICC sent a high-level delegation to Dong'ao Health from September 6-10, including Chairman Mr. Yang Shengnan, CEO Ms. Barbara Tan, CFO Mr. Jon Lim, Chief Scientist Mr. Chen Yanming, and shareholder Mr. Chen Laifu.
The delegation conducted on-site inspections of Dong'ao Health's four core segments—the Health and Wellness Center, Cell R&D Center, under-construction Alzheimer's Disease Care Town, and partner "Anhe Meige Medical Aesthetic Hospital"—to evaluate potential synergies. The parties agreed to establish a joint laboratory, implement a technology exchange mechanism, integrate BICC's network of over 3,000 agents in Southeast Asia with Dong'ao Health's domestic wellness channels, and co-establish stem cell transfusion centers to promote standardized clinical services.
These dual developments exemplify Shineco's two-pronged strategy of "technology development plus ecosystem synergy." Technologically, the partnership combines complementary R&D capabilities and application scenarios. From a market perspective, the contracted revenue and BICC's international channels create a strategy of "a solid domestic base + expansion into new international markets." Financially, the deal improves short-term cash flow and enhances long-term profitability through technology leverage and market expansion.
"These advancements demonstrate the effective operation of our complete value chain from technology to industry to capital," CEO Jennifer Zhan emphasized. "Shineco remains committed to deepening our technology industrialization efforts and advancing international partnerships to deliver sustainable returns for our shareholders."
Shineco will provide regular updates on the contract's execution and the collaboration with BICC in accordance with NASDAQ disclosure rules.
About Xi'an Dong'ao Health Management Co., Ltd.
Xi'an Dong'ao Health provides GMP-compliant biostorage and clinical cell applications, delivering integrated health management via "Prevention-Intervention-Maintenance" protocols.
About BICC Pte Ltd
BICC Pte Ltd is a Singapore-based innovative biotechnology holding company with an extensive commercial network of over 3,000 agents across Southeast Asia, which provides a powerful distribution channel for its portfolio of advanced therapies and wellness products. Founded in 2024, the company unites a world-class team of scientists and medical experts specializing in stem cell treatments and artificial intelligence. Leveraging its strategic presence across Asia and proprietary technologies—including patented serum-free media, iPSC-derived therapies, and clinically proven wound-healing applications—BICC is positioned at the cutting edge of integrated health solutions. For more information about BICC, please visit www.BICC.sg.
About Shineco, Inc.
Shineco, Inc. is dedicated to improving quality of life through the development and provision of safe, efficient, and high-quality health and medical products and services. The Company's core business focuses on induced pluripotent stem cell (iPSC) technology platforms and extracellular vesicle-derived products. For more information, please visit www.biosisi.com.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by words such as "may," "will," "should," "could," "intend," "expect," "plan," "budget," "forecast," "anticipate," "believe," "estimate," "forecast," "potential," "continue," "evaluate" or similar words. Forward-looking statements should not be relied upon as they are neither historical facts nor guarantees of future performance. Rather, they are based solely on our current beliefs, expectations and assumptions about future business, future plans and strategies, forecasts, expected events and trends, economics, and other future conditions. Examples of forward-looking statements include, among other things, our innovation and market position in our products and services, our competitive advantages, and our expectation that the 5-minute cardiac test will be one of the leading products in this field to meet the need for test results immediately upon intake. Please do not rely on any forward-looking statements. Actual results may differ materially from those indicated in historical results or forward-looking statements due to various factors, including, but not limited to, the Company's ability to raise additional capital, its ability to maintain and grow its business, the variability of its results of operations, its ability to maintain and enhance its brand, its ability to develop and introduce new products and services, its ability to obtain all necessary regulatory approvals in the jurisdictions in which it intends to market and sell its products, companies to be acquired, successful integration of technology and assets into its portfolio of products and services, marketing and other business development initiatives, industry competition, general government regulations, economic conditions, impact of the COVID-19 pandemic, reliance on key personnel, attracting, hiring and retaining personnel with the technical skills and experience required to meet customer requirements and protecting its intellectual property. Shineco encourages you to review these and other factors that may affect its future performance in its filings with the Securities and Exchange Commission. The forward-looking statements in this press release are based only on information currently available to us and are made only as of the date of this press release, and Shineco undertakes no obligation to update any forward-looking statements, except as required by applicable rules and regulations.
For more information, please contact:
Shineco, Inc.
Email: [email protected]
Phone: +86-10-68130220
View original content:https://www.prnewswire.com/news-releases/shineco-sisi-ignites-growth-8-7m-tech-deal--major-singapore-alliance-unleash-dual-engines-302554831.html
SOURCE Shineco,Inc.